NovellusDx has receivd a new patent by the name of "Methods and Systems for Identifying Patient Specific Driver Mutations."
The company's FACT system stands to gain from the patent, as it is a valuable tool for both health professionals and pharmaceutical companies seeking to aid patients in securing medication and solutions for their individual mutations.
In October 2016, Cancer Discovery published a study that was headed by Dr. Scott Kopetz of the MD Anderson Cancer Center to explain that Variants of Uncertain Significance may find more difficulty in receiving regular treatments. The findings of this study go hand-in-hand with the patent that NovellusDx has secured.
"We demonstrated that the functional significance of NGS data can identify drug resistance earlier than conventional tools and propose alternative treatment options," Dr. Gabi Tarcic, vice president of research and development of NovellusDx, said.
NovellusDx will present its findings at the American Society of Clinical Oncology conference from June 3-7 in Chicago and at the BIO2017 meeting in San Diego, California from June 19-22.
Alerts Sign-up